<DOC>
	<DOCNO>NCT00291369</DOCNO>
	<brief_summary>The PERCY Quattro trial design evaluate survival benefit two cytokine treatment , Interleukin-2 ( IL2 ) and/or alpha interferon ( IFN ) , patient intermediate chance response metastatic renal cell carcinoma . Eligible patient randomly assign two-by-two factorial design either medroxyprogesterone ( MPA ) , subcutaneous IFN , subcutaneous IL2 , combination IFN IL2 . The primary objective study overall survival ; secondary objective progression-free survival , response rate , toxicity , quality life .</brief_summary>
	<brief_title>Cytokines Patients With Metastatic Renal Cell Carcinoma Intermediate Prognosis</brief_title>
	<detailed_description>The PERCY Quattro trial design evaluate survival benefit Interleukin-2 ( IL2 ) and/or alpha interferon ( IFN ) patient intermediate chance response metastatic renal cell carcinoma . The primary objective overall survival , secondary objective progression-free survival , response rate , toxicity , quality life assess induction treatment ( week 10 ) . Patients 18 year age eligible histologically confirm , clearly progressive metastatic renal carcinoma , one metastatic organ good performance status ( Karnofsky score ≥80 % ) , one metastatic organ Karnofsky score 80 % , normal blood liver function creatinine level &lt; = 160 µmol/L . Eligible patient randomly assign two-by-two factorial design either medroxyprogesterone ( MPA ) , subcutaneous IFN , subcutaneous IL2 , combination IFN IL2 . The planned sample size 456 patient ( 114 four arm ) . MPA give orally 200 mg daily . IFN give subcutaneously 9 million IU three time week . IL2 give subcutaneously four-week schedule : 9 million IU twice daily five day follow two-day rest , , follow three week , 9 million IU twice daily two day 9 million IU daily follow three day ; week rest , identical 4-week cycle administer . IFN IL2 combination give use identical route , schedule dos except reduction IFN dose 6 million IU per injection .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Medroxyprogesterone</mesh_term>
	<criteria>Progressive histologically proven metastatic renal cell carcinoma . Patient 1 metastatic site Karnofsky = 80 % 1 metastatic site Karnofsky &gt; = 80 % . Age &gt; = 18 No widefield radiation therapy 6 week least . No active brain metastasis . Blood value within limit normal ( hematocrit &gt; 30 % leukocyte count &gt; = 4x109/l platelet count &gt; = 120x109/l ) . Creatinine &lt; 150 µmol/l bilirubin &lt; = normal . Female patient childbearing potential : effective method contraception necessary . Written , voluntary , informed consent . Previous treatment cytokine . Only one metastatic organ Karnofsky = 90 % 100 % ( inclusion good prognosis group ) . More one metastatic organ ( least one metastasis liver ) &lt; 12 month initial diagnosis diagnosis metastasis . Active brain metastasis . Patient concurrent grade III/IV heart disorder ( congestive heart failure , coronary artery disease , uncontrolled hypertension , severe arrhythmia , etc ) and/or stroke volume &lt; 50 % . Severe pulmonary , hepatic , renal disease potentially aggravate treatment . Severe concurrent infection necessitate antibiotic Patient know HIV AIDSrelated disease , presence HB antigen know chronic hepatitis . Previous allograft . Patient corticosteroid treatment . Previous concurrent primary malignancy site ( except basocellular skin cancer cervical cancer situ ) Pregnant lactate woman . Followup difficult geography personal circumstance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2006</verification_date>
	<keyword>Metastatic renal cell carcinoma</keyword>
	<keyword>Interleukin-2</keyword>
	<keyword>Interferon alfa</keyword>
	<keyword>Cytokines</keyword>
	<keyword>Survival</keyword>
</DOC>